Dr. Shi is a molecular biologist at HMRI Cardiovascular Research Institute.

Dr. Shi received her MD from the Henan Medical University in 1996 and her PhD in cardiovascular pathology from the Peking Union Medical College, Beijing, China in 2004. Dr. Shi pursued her postdoctoral studies at Harvard Medical School & Brigham and Women’s Hospital in Boston, in 2005. She was an instructor at Harvard Medical School & Brigham and Women’s Hospital, Boston, USA in 2010.

Dr. Shi obtained training in redox regulation and inflammation in cardiovascular disease during her graduate studies. After graduation, she investigated the molecular mechanisms underlying the development of primary amyloid cardiomyopathy and the role of inflammation in metabolic regulation within the cardiovascular system.

Her interests in translational research led her to join Dr. Kloner’s group in 2012 to study the mechanisms of cardioprotection. Her research focused on the cardioprotective effects of drug, hypothermia and stem cell on myocardial infarction. She has observed that a mitochondrial-targeting peptide (Bendavia) improved expression of mitochondrial energy metabolism genes and prevented myocardial matrix remodeling in the noninfarcted border zone of infarcted hearts and she presented her work in American Heart Association Scientific Sessions and Experimental Biology 2013, 2014 and 2016. Dr. Shi is now working on cardioprotective agents to preserve organ function and improve survival during experimental hemorrhagic shock. Recently, she presented her work in American Heart Association Scientific Sessions 2017.